Drug intelligence / Profile preview

LCE64

Development stage: Preclinical
Lead developer: Western University
Modality: Peptides
Administration: Intravenous

Overview

LCE64 is a novel, non-RGD-containing octapeptide ligand (sequence: KTKKVHSQ) that targets integrin αvβ3. Discovered using a "beads on a bead" screening approach of a linear octapeptide one-bead-one-compound (OBOC) library, LCE64 binds to purified integrin αvβ3 with high affinity ($K_D$ of approximately 4.7 nM to 16.3 nM). Unlike traditional RGD-containing peptides, LCE64 does not affect cell adhesion, morphology, or angiogenesis, making it a potentially safer targeting vehicle for molecular imaging and diagnostic applications in integrin αvβ3-expressing cancers, such as breast cancer.

Other names: KTKKVHSQ

Targets

αVβ3 (Integrin αVβ3)

Beyond the preview

Go deeper on LCE64.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LCE64.

Explore the full profile